The impact of reinsurance of gene therapies on employer financial risk

This is the authors' abstract. We don't add key points for this paper.

FINDS its footing, cancer care stakeholders are raising questions about the fate of many federal policies that will make an impact on health care as well as on oncologists, payers, and patients.